Early Phase 1 Parkinson's Disease Trial, Recruiting NCT06189170 Sponsor: Kariya Pharmaceuticals Condition: Parkinson's Disease
Back to Parkinsons Disease

Early Phase 1 Parkinson's Disease Trial, Recruiting

NCT06189170
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who a doctor has assessed as generally healthy, based on a full medical review including their medical history, physical examination, any medications they take, vital signs, heart tracings (ECG and Holter monitor), and blood or lab tests.
  • People who have been clinically diagnosed with Parkinson's disease using a recognised set of diagnostic guidelines called the United Kingdom Brain Bank criteria.

Who may not be able to join:

  • People who have a significant physical or mental health condition (other than Parkinson's disease) that could interfere with the study — this may include conditions affecting the nervous system, mental health, hormones, heart, lungs, digestive system, liver, or kidneys, as assessed by the study doctor.
  • People who have a significant neurological condition other than Parkinson's disease — including a stroke or mini-stroke (TIA) within the past 12 months, problems with memory or thinking, a seizure within the past 5 years, or a head injury with loss of consciousness within the past 6 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Principal Investigator: Ezanul A Wahab, MD, MAC

Phone: 5170029

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Kariya Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Adverse event (AE) reporting; 12-lead electrocardiogram (ECG); Continous ECG monitoring; Blood pressure; Pulse rate; Temperature; Biochemistry parameters in blood samples; Haematology parameters in blood samples; Urine samples; Coagulation parameters in blood samples; Serology parameters in blood samples; Alcohol breath test; Height; Body weight; Assessments of body parts; Injection site reactions

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov